New trial
BURN Study: Buffered Lidocaine in Reducing Pain From Prostate Biopsy
- Trial ID
- NCT06661902 on ClinicalTrials.gov
- Cancer type
- Prostate Cancer
- Published in
- New in Oncology - May 21, 2025
This phase I/II trial evaluates whether buffered lidocaine during prostate biopsy can reduce procedural pain compared to standard lidocaine. The study, focusing on resectable prostate cancer patients, is led by the University of Washington.
More in prostate cancer
-
Trial result · Oct 22, 2026 · NCT03732820
Olaparib (PARP inhibitor) + Abiraterone (CYP17 AR-pathway inhibitor) Extends rPFS in Non‑BRCA mCRPC (PROpel) -
New trial · Oct 15, 2026 · NCT07813637
Phase 1 JANX013 PSMA×CD28 costimulation combines with JANX007 PSMA×CD3 T-cell engagement -
New trial · Oct 15, 2026 · NCT07832292
Phase 2 JNJ-101556143 uses an AR-BRD4 induced-proximity mechanism in resistant prostate cancer -
New trial · Oct 8, 2026 · NCT07824349
Phase 1a/1b JUR-003 KLK2×CD3 bispecific T‑cell engager in metastatic prostate cancer -
New trial · Oct 1, 2026 · NCT07803653
Phase 1 FH-STEAP1 IL-18 CAR T tests STEAP1-targeted CAR-T armored with IL-18